MedPath

Effect of Rosa canina on non alcoholic fatty liver

Phase 1
Conditions
on alcoholic fatty liver(NAFLD).
Fatty (change of) liver, not elsewhere classified
Registration Number
IRCT2017011514333N65
Lead Sponsor
Vice chancellor for research, Kermanshah University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Other
Sex
All
Target Recruitment
70
Inclusion Criteria

Diagnosis of non-alcoholic fatty diseases based on AST and ALT level more than 30 in men and 20 in women and also liver ultrasound; Aged between 30-65 years; BMI greater than 25;
Non-use of antioxidant supplements during one month prior to sampling; Non-acute cardiac disease, renal, infectious, diabetes, hepatitis B or C and other liver diseases; Not being on an intense increasing or decreasing diet weight during the last three months prior to sampling; lack of effective drugs on weight during the last three months prior to sampling; not using medications that may be associated with the disease (methotrexate, amiodarone, tamoxifen, corticosteroids, valproic acid).
Exclusion criteria: Not wanting to continue the study; Use of drugs that affect the liver; The risk of diseases that require special treatment; pregnancy during the study.

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
iver enzymes. Timepoint: Baseline, 48 hours after the end of the study (study will take 8 weeks). Method of measurement: Based on the results of blood tests (including ALT and AST).
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath